Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience

PURPOSE: To compare the pathologic complete response (pCR) rate and relapse-free survival (RFS) and overall survival (OS) after neoadjuvant systemic chemotherapy (NST) in patients with breast cancer with and without deleterious BRCA1 and BRCA2 mutations. PATIENTS AND METHODS: A total of 317 women wh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Arun, Banu, Bayraktar, Soley, Liu, Diane D., Gutierrez Barrera, Angelica M., Atchley, Deann, Pusztai, Lajos, Litton, Jennifer Keating, Valero, Vicente, Meric-Bernstam, Funda, Hortobagyi, Gabriel N., Albarracin, Constance
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2011
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874218/
https://ncbi.nlm.nih.gov/pubmed/21900106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.2682
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares